Sugi Predict

Sugi Predict / Targets / PPM1F

PPM1F

Protein phosphatase 1F · P49593 · PPM1F on Sugi Atlas →

0 patent compounds predicted against PPM1F, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PPM1F by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PPM1F binder may also engage these)

ProteinNameSimilarity
Q9WVR7 — 0.991 Q9WVR7 →
Q8CGA0 — 0.990 Q8CGA0 →
PKN1 Serine/threonine-protein kinase N1 0.957 landscape →
Q8BNV1 — 0.953 Q8BNV1 →
SPHK2 Sphingosine kinase 2 0.953 landscape →
Q8IZ69 — 0.952 Q8IZ69 →
Q9DD16 — 0.951 Q9DD16 →
Q8N1F8 — 0.951 Q8N1F8 →
MRM1 rRNA methyltransferase 1, mitochondrial 0.950 landscape →
PKN3 Serine/threonine-protein kinase N3 0.950 landscape →
A1A4I4 — 0.950 A1A4I4 →
O35465 — 0.950 O35465 →
Q8N9H8 — 0.950 Q8N9H8 →
Q17QS4 — 0.950 Q17QS4 →
Q3B7U9 — 0.949 Q3B7U9 →
POLM DNA-directed DNA/RNA polymerase mu 0.949 landscape →
Q6P9U1 — 0.948 Q6P9U1 →
Q8TDF6 — 0.948 Q8TDF6 →
FKBP8 Peptidyl-prolyl cis-trans isomerase FKBP8 0.948 landscape →
Q5SWZ9 — 0.948 Q5SWZ9 →
E1BE10 — 0.948 E1BE10 →
Q6RFH5 — 0.947 Q6RFH5 →
Q8N2A8 — 0.947 Q8N2A8 →
Q9JIW4 — 0.947 Q9JIW4 →
Q9JIA7 — 0.947 Q9JIA7 →
Q9ESG9 — 0.947 Q9ESG9 →
E2RD63 — 0.947 E2RD63 →
Q86UR1 — 0.947 Q86UR1 →
Q5T9C9 — 0.946 Q5T9C9 →
HDAC10 Polyamine deacetylase HDAC10 0.946 landscape →